Payment overview · 2025
General Payments
$797.48
37 reported records · 17 companies
Healthcare provider profile · identity verified
Robert G Drake, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOMERSET, KY · NPI 1528151685
Verified facts
What the public records show
CMS Open Payments records show Robert G Drake, MD received $797.48 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 739 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.25 | 25.2% | 16 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $197.40 | 24.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $100.00 | 12.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.66 | 6.2% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.32 | 4.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.85 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.20 | 2.8% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $20.77 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.87 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.92 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.18 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.96 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.92 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.15 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.97 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.96 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $797.48 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $201.25 | 16 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $197.40 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $154.55 | 11 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.70 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.81 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 739 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 453 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
453 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
453 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
263 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
140 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
61 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
739 | 90 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1320 | 288 |
| Levothyroxine Sodium | Levothyroxine Sodium | 962 | 192 |
| Omeprazole | Omeprazole | 888 | 173 |
| Gabapentin | Gabapentin | 839 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 835 | 122 |
| Eliquis | Apixaban | 739 | 90 |
| Lisinopril | Lisinopril | 739 | 183 |
| Alprazolam | Alprazolam | 616 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 590 | 138 |
| Furosemide | Furosemide | 574 | 130 |
| Potassium Chloride | Potassium Chloride | 543 | 113 |
| Metformin Hcl | Metformin Hcl | 468 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 456 | 93 |
| Jardiance | Empagliflozin | 453 | 72 |
| Atenolol | Atenolol | 405 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 92 |
| Citalopram Hbr | Citalopram Hydrobromide | 387 | 79 |
| Sertraline Hcl | Sertraline Hcl | 387 | 65 |
| Montelukast Sodium | Montelukast Sodium | 367 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 81 |
| Lorazepam | Lorazepam | 320 | 44 |
| Simvastatin | Simvastatin | 298 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 68 |
| Memantine Hcl | Memantine Hcl | 292 | 55 |
| Losartan Potassium | Losartan Potassium | 287 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 67 |
| Mounjaro | Tirzepatide | 263 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 234 | 53 |
| Allopurinol | Allopurinol | 229 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 229 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 65 |
| Carvedilol | Carvedilol | 219 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 211 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 210 | 129 |
| Promethazine Hcl | Promethazine Hcl | 208 | 39 |
| Tramadol Hcl | Tramadol Hcl | 201 | 46 |
| Trazodone Hcl | Trazodone Hcl | 200 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 47 |
| Xarelto | Rivaroxaban | 196 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 193 | 74 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 187 | 66 |
| Famotidine | Famotidine | 185 | 31 |
| Clonidine Hcl | Clonidine Hcl | 175 | 41 |
| Mirtazapine | Mirtazapine | 174 | 27 |
| Buspirone Hcl | Buspirone Hcl | 167 | 28 |
| Tradjenta | Linagliptin | 147 | 16 |
| Trulicity | Dulaglutide | 140 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 131 | 21 |
| Ibuprofen | Ibuprofen | 130 | 38 |
| Prednisone | Prednisone | 119 | 61 |
| Azithromycin | Azithromycin | 117 | 87 |
| Clonazepam | Clonazepam | 113 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 27 |
| Methocarbamol | Methocarbamol | 111 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 20 |
| Baclofen | Baclofen | 108 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 107 | 88 |
| Donepezil Hcl | Donepezil Hcl | 104 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 74 |
| Meloxicam | Meloxicam | 102 | 27 |
| Metolazone | Metolazone | 99 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 98 | 37 |
| Farxiga | Dapagliflozin Propanediol | 97 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | 19 |
| Divalproex Sodium | Divalproex Sodium | 94 | 12 |
| Levetiracetam | Levetiracetam | 91 | 11 |
| Nystatin | Nystatin | 88 | 35 |
| Nifedipine Er | Nifedipine | 86 | 21 |
| Warfarin Sodium | Warfarin Sodium | 85 | suppressed |
| Ezetimibe | Ezetimibe | 82 | 24 |
| Lansoprazole | Lansoprazole | 82 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 17 |
| Entresto | Sacubitril/Valsartan | 80 | suppressed |
| Fluconazole | Fluconazole | 80 | 26 |
| Meclizine Hcl | Meclizine Hcl | 79 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 17 |
| Risperidone | Risperidone | 77 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | suppressed |
| Bumetanide | Bumetanide | 74 | 11 |
| Aripiprazole | Aripiprazole | 73 | 13 |
| Levofloxacin | Levofloxacin | 73 | 58 |
| Spironolactone | Spironolactone | 72 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 16 |
| Finasteride | Finasteride | 71 | 15 |
| Amoxicillin | Amoxicillin | 70 | 44 |
| Brilinta | Ticagrelor | 68 | 12 |
| Linzess | Linaclotide | 68 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 42 |
| Diazepam | Diazepam | 65 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 64 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 19 |
| Pregabalin | Pregabalin | 63 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 61 | 61 |
| Januvia | Sitagliptin Phosphate | 61 | 12 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 11 |
| Latanoprost | Latanoprost | 55 | 12 |
| Topiramate | Topiramate | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 12 |
| Celecoxib | Celecoxib | 48 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 32 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 45 | 15 |
| Gemfibrozil | Gemfibrozil | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | 11 |
| Glipizide | Glipizide | 42 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 26 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Amantadine | Amantadine Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 14 |
| Gemtesa | Vibegron | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Felodipine Er | Felodipine | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 13 |
| Mupirocin | Mupirocin | 31 | 21 |
| Primidone | Primidone | 31 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 11 |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 27 | 27 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lexapro | Escitalopram Oxalate | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 15 |
| Tobramycin | Tobramycin | 21 | 15 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 11 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 13 |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $797.48 · 37 records | PFIZER INC. | AIRSUPRA, BREZTRI, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, Da Vinci Surgical System, ELIQUIS, EVENITY, FANAPT, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, LEQVIO, NURTEC ODT, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, ZAVZPRET | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error